fbpx
QQQ
-8.74
317.42
-2.83%
DIA
+ 3.08
312.10
+ 0.98%
SPY
-1.84
385.40
-0.48%
TLT
-1.08
139.99
-0.78%
GLD
-1.63
160.75
-1.02%

Biogen Blitzed, Hits Lowest Level Since March

by
June 7, 2016 11:46 am
Share to Linkedin Share to Twitter Share to Facebook Share to Print License More
Biogen Blitzed, Hits Lowest Level Since March

Biogen Inc (NASDAQ: BIIB) shares are trading lower by $37 (12 percent) at $252.84 in Tuesday's session. The catalyst for the sharp decline is the results from a Phase 2 study of Opicinumab that missed both its primary and secondary endpoints.

The slaughter from the pre-market session has spilled over into the regular session. After a sharply lower open, it could only manage a $0.28 bounce to $264.73 before another wave of sellers came into the issue.

So far, it has reached $250.87 and is attempting to rebound. That marks the lowest price for the issue since it bottomed on March 29 at $246.74.

Biogen made its all-time high in March 2015 at $480.18 and traded down to $242.07 in February.


Related Articles

Stocks Which Set New 52-Week High Yesterday, July 25th

Stocks That Made New 52-Week Highs Earlier Include: Adobe, S&P Global, Baxter, Salesforce, Microsoft, Biogen, Becton, Norfolk Southern, Target, IHS Markit, Tiffany, Eli Lilly, Thermo Fisher, Facebook, FLIR Systems, Medtronic, and Mastercard

Stocks Which Set New 52-Week High Yesterday, July 24th:

PreMarket Prep Recap For July 6: Digesting Biogen's News With Adam Feuerstein; A Sector Breakdown With Dan Russo